| Steven Koerner, DO | |
|
1301 Route 72 W, Suite 300, Manahawkin, NJ 08050-2417 | |
| (609) 597-6513 | |
| (609) 597-4593 |
| Full Name | Steven Koerner |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 35 Years |
| Location | 1301 Route 72 W, Manahawkin, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558434308 | NPI | - | NPPES |
| 0411885003 | Other | NJ | CIGNA |
| 223012814 | Other | NJ | QUALCARE |
| 6203001 | Medicaid | NJ | |
| F01493 | Other | NJ | HEALTH NET |
| 0714723000 | Other | NJ | AMERIHEALTH |
| 223012814 | Other | NJ | DEVON |
| 223012814 | Other | NJ | ATLANTICARE |
| 223012814 | Other | NJ | HORIZON |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | MB55609 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Southern Ocean Medical Center | Manahawkin, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hackensack Meridian Health Medical Group - Specialty Care Pc | 9133032519 | 1090 |
News Archive
Scientists in Portugal just found a new molecular mechanism behind colorectal cancer in which a mutated and a normal, but over-expressed, gene cooperate and are both needed to create the disease.
ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics, announced today it has entered into a collaboration in which Cephalon Australia (a wholly owned subsidiary of Cephalon, Inc.) will apply ImmunGene's interferon payload technology to up to six of its new drug targets for cancers.
A team of international scientists has recently demonstrated the usefulness of cetylpyridinium chloride-containing mouthwashes in inhibiting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and reducing the risk of viral transmission. The study is currently available on the bioRxiv* preprint server.
Although breast cancer mortality has declined in the U.S., it is still the most frequently diagnosed cancer and the leading cause of cancer deaths in women under 60 years old.
Epilepsy prevalence and incidence is greater than earlier thought in the United States. The latest study shows that one in every 26 people in the United States will develop epilepsy at some point in their life. Experts believe this new revelation calls for more attention and funding for the disease.
› Verified 6 days ago
| Entity Name | Hackensack Meridian Health Medical Group - Specialty Care Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215989249 PECOS PAC ID: 9133032519 Enrollment ID: O20031111000524 |
News Archive
Scientists in Portugal just found a new molecular mechanism behind colorectal cancer in which a mutated and a normal, but over-expressed, gene cooperate and are both needed to create the disease.
ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics, announced today it has entered into a collaboration in which Cephalon Australia (a wholly owned subsidiary of Cephalon, Inc.) will apply ImmunGene's interferon payload technology to up to six of its new drug targets for cancers.
A team of international scientists has recently demonstrated the usefulness of cetylpyridinium chloride-containing mouthwashes in inhibiting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and reducing the risk of viral transmission. The study is currently available on the bioRxiv* preprint server.
Although breast cancer mortality has declined in the U.S., it is still the most frequently diagnosed cancer and the leading cause of cancer deaths in women under 60 years old.
Epilepsy prevalence and incidence is greater than earlier thought in the United States. The latest study shows that one in every 26 people in the United States will develop epilepsy at some point in their life. Experts believe this new revelation calls for more attention and funding for the disease.
› Verified 6 days ago
| Entity Name | Meridian Medical Group-specialty Care Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942362587 PECOS PAC ID: 6507962206 Enrollment ID: O20070425000673 |
News Archive
Scientists in Portugal just found a new molecular mechanism behind colorectal cancer in which a mutated and a normal, but over-expressed, gene cooperate and are both needed to create the disease.
ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics, announced today it has entered into a collaboration in which Cephalon Australia (a wholly owned subsidiary of Cephalon, Inc.) will apply ImmunGene's interferon payload technology to up to six of its new drug targets for cancers.
A team of international scientists has recently demonstrated the usefulness of cetylpyridinium chloride-containing mouthwashes in inhibiting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and reducing the risk of viral transmission. The study is currently available on the bioRxiv* preprint server.
Although breast cancer mortality has declined in the U.S., it is still the most frequently diagnosed cancer and the leading cause of cancer deaths in women under 60 years old.
Epilepsy prevalence and incidence is greater than earlier thought in the United States. The latest study shows that one in every 26 people in the United States will develop epilepsy at some point in their life. Experts believe this new revelation calls for more attention and funding for the disease.
› Verified 6 days ago
| Entity Name | Ea Health - New Jersey Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063186641 PECOS PAC ID: 6103222039 Enrollment ID: O20210901001290 |
News Archive
Scientists in Portugal just found a new molecular mechanism behind colorectal cancer in which a mutated and a normal, but over-expressed, gene cooperate and are both needed to create the disease.
ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics, announced today it has entered into a collaboration in which Cephalon Australia (a wholly owned subsidiary of Cephalon, Inc.) will apply ImmunGene's interferon payload technology to up to six of its new drug targets for cancers.
A team of international scientists has recently demonstrated the usefulness of cetylpyridinium chloride-containing mouthwashes in inhibiting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and reducing the risk of viral transmission. The study is currently available on the bioRxiv* preprint server.
Although breast cancer mortality has declined in the U.S., it is still the most frequently diagnosed cancer and the leading cause of cancer deaths in women under 60 years old.
Epilepsy prevalence and incidence is greater than earlier thought in the United States. The latest study shows that one in every 26 people in the United States will develop epilepsy at some point in their life. Experts believe this new revelation calls for more attention and funding for the disease.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Steven Koerner, DO 1301 Route 72 W, Suite 300, Manahawkin, NJ 08050-2417 Ph: (609) 597-6513 | Steven Koerner, DO 1301 Route 72 W, Suite 300, Manahawkin, NJ 08050-2417 Ph: (609) 597-6513 |
News Archive
Scientists in Portugal just found a new molecular mechanism behind colorectal cancer in which a mutated and a normal, but over-expressed, gene cooperate and are both needed to create the disease.
ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics, announced today it has entered into a collaboration in which Cephalon Australia (a wholly owned subsidiary of Cephalon, Inc.) will apply ImmunGene's interferon payload technology to up to six of its new drug targets for cancers.
A team of international scientists has recently demonstrated the usefulness of cetylpyridinium chloride-containing mouthwashes in inhibiting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and reducing the risk of viral transmission. The study is currently available on the bioRxiv* preprint server.
Although breast cancer mortality has declined in the U.S., it is still the most frequently diagnosed cancer and the leading cause of cancer deaths in women under 60 years old.
Epilepsy prevalence and incidence is greater than earlier thought in the United States. The latest study shows that one in every 26 people in the United States will develop epilepsy at some point in their life. Experts believe this new revelation calls for more attention and funding for the disease.
› Verified 6 days ago
Meghavi J Patel, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1140 Route 72 W, Manahawkin, NJ 08050 Phone: 609-597-6011 | |
Vincent Abenante, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 588 E Bay Ave, Suite 1, Manahawkin, NJ 08050 Phone: 609-489-0220 Fax: 609-489-0228 | |
Dr. Michael J. Kirk Jr., D.O., PHARM.D. Gastroenterology Medicare: Medicare Enrolled Practice Location: 1140 Route 72 W, Manahawkin, NJ 08050 Phone: 609-978-3331 | |
Frank C Labue, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 1301 Route 72 W, Suite 300, Manahawkin, NJ 08050 Phone: 609-597-6513 Fax: 609-597-4593 | |
Dr. Kristophe Mikhail, Anthony Anderson, MD Gastroenterology Medicare: Medicare Enrolled Practice Location: 1140 Route 72 W, Manahawkin, NJ 08050 Phone: 609-597-6011 | |
Helio J Malinverni, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 1301 Route 72 W, Suite 300, Manahawkin, NJ 08050 Phone: 609-597-6513 Fax: 609-597-4593 | |
Dr. Harsh Virendra Bhavsar, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1140 Nj-72 West, Manahawkin, NJ 08050 Phone: 610-237-4000 |